The treatment of EGFR and HER2 overexpressing gastric cancer cells with Afatinib (a pan-ErbB2 family TKI) and lapatinib (EGFR, ErbB2 inhibitor) reduced PD-L1 expression levels [72]. This evidence concerns the gene CD274 and gastric cancer.